Neuropeptide Y May Serve as Both a Diagnostic Marker and Protective Agent in Alzheimer's Disease
A systematic review of 19 studies found that neuropeptide Y (NPY) levels are reduced in Alzheimer's patients and that NPY shows neuroprotective effects in disease models, suggesting potential as both a biomarker and therapeutic target.
Quick Facts
What This Study Found
NPY levels are reduced in cerebrospinal fluid and plasma of Alzheimer's patients, and NPY demonstrates neuroprotective properties in both in vitro and in vivo AD models.
Key Numbers
NPY is a 36-amino-acid peptide. AD is one of the most common neurodegenerative diseases.
How They Did This
Systematic review of 19 published studies identified through keyword searches for 'Alzheimer's disease and neuropeptide Y' and related terms across scientific databases.
Why This Research Matters
Early detection of Alzheimer's disease remains a major clinical challenge, and current treatments have limited effectiveness. If NPY can reliably indicate early AD and also protect neurons, it could serve a dual role as both a diagnostic tool and a basis for new therapies.
The Bigger Picture
As the global population ages, Alzheimer's disease is becoming an increasingly urgent health crisis. The search for reliable biomarkers and new therapeutic approaches is critical. NPY's dual potential as a diagnostic marker and neuroprotective agent makes it a particularly promising research target, though more recent clinical studies are needed to confirm these findings.
What This Study Doesn't Tell Us
Many of the reviewed studies are older and used small sample sizes. Results on NPY levels in AD patients were not entirely consistent (some showed reductions, others no change). Most neuroprotective evidence comes from animal models and cell studies, not human clinical trials.
Questions This Raises
- ?Can NPY blood levels reliably distinguish early-stage Alzheimer's from normal aging?
- ?What is the best route of administration for NPY-based neuroprotective therapy?
- ?How do NPY levels change across different stages of Alzheimer's disease progression?
Trust & Context
- Key Stat:
- 19 studies reviewed Consistently showing reduced NPY levels and neuroprotective effects in Alzheimer's models
- Evidence Grade:
- Preliminary evidence based on a systematic review of mostly preclinical and small clinical studies. The neuroprotective findings need validation in larger human trials.
- Study Age:
- Published in 2024. Reviews literature spanning multiple decades of NPY-Alzheimer's research.
- Original Title:
- The Role of Neuropeptide Y in the Pathogenesis of Alzheimer's Disease: Diagnostic Significance and Neuroprotective Functions.
- Published In:
- Neurology international, 16(6), 1318-1331 (2024)
- Authors:
- Shapovalova, Ksenia, Zorkina, Yana, Abramova, Olga, Andryushchenko, Alisa, Chekhonin, Vladimir, Kostyuk, Georgy
- Database ID:
- RPEP-09247
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is neuropeptide Y and what does it do in the brain?
NPY is a 36-amino-acid signaling molecule found throughout the central and peripheral nervous system. It plays roles in appetite regulation, stress response, memory, and neuronal survival, and it can promote the growth of new brain cells.
Could NPY be used to detect Alzheimer's disease early?
Possibly. Multiple studies have found reduced NPY levels in the cerebrospinal fluid and blood of Alzheimer's patients. However, results haven't been entirely consistent, and more research with modern techniques and larger groups is needed before NPY can be used as a reliable diagnostic marker.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09247APA
Shapovalova, Ksenia; Zorkina, Yana; Abramova, Olga; Andryushchenko, Alisa; Chekhonin, Vladimir; Kostyuk, Georgy. (2024). The Role of Neuropeptide Y in the Pathogenesis of Alzheimer's Disease: Diagnostic Significance and Neuroprotective Functions.. Neurology international, 16(6), 1318-1331. https://doi.org/10.3390/neurolint16060100
MLA
Shapovalova, Ksenia, et al. "The Role of Neuropeptide Y in the Pathogenesis of Alzheimer's Disease: Diagnostic Significance and Neuroprotective Functions.." Neurology international, 2024. https://doi.org/10.3390/neurolint16060100
RethinkPeptides
RethinkPeptides Research Database. "The Role of Neuropeptide Y in the Pathogenesis of Alzheimer'..." RPEP-09247. Retrieved from https://rethinkpeptides.com/research/shapovalova-2024-the-role-of-neuropeptide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.